Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B study 9763

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8325-8331

  Miller, Antonius A ^a,f   Rosner, Gary L ^b   Egorin, Merrill J ^c   Hollis, Donna ^b   Lichtman, Stuart M ^d   Ratain, Mark J ^e  

^a WAKE FOREST UNIVERSITY   (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE CALCULATION; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; LETHARGY; LEUKEMIA; LUNG CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; NEUTROPENIA; PHARYNGITIS; PRIORITY JOURNAL; SENSORY NEUROPATHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BODY SURFACE AREA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 11144236820     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1078     Document Type: Article

References (27)

1. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-71.
2. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225-35.
3. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst (Bethesda) 1990;82:323-5.
4. Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? Cancer Chemother Pharmacol 1993;32:411-8.
5. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-611.
6. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16:2297-8.
7. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Investig New Drugs 2001;82:171-7.
8. Baker SD, Verweij J, Rowinsky EK, et al. Role of body-surface area in dosing of investigational anticancer agents in adults: 1991-2001. J Natl Cancer Inst (Bethesda) 2002;94:1883-8.
9. Miller AA. Body surface area in dosing anticancer agents: scratch the surface! J Natl Cancer Inst (Bethesda) 2002;94:1822-3.
10. Egorin MJ. Horseshoes, hand grenades, and BSA-based dosing: aiming for a target. J Clin Oncol 2003;21:182-3.
11. Dooley MJ, Poole SG. Poor correlation between body surface area and glomerular filtration rate. Cancer Chemother Pharmacol 2000;46:523-6.
12. Freireich EJ, Gehan EA, Rail DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1996;50:219-31.
13. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond) 1989;22:665-7.
14. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 2004;22:2061-8.
15. Glantz MJ, Choy H, Kearns CM, et al. Paclitaxel disposition in plasma and central nervous system of humans and rats with brain tumors. J Natl Cancer Inst (Bethesda) 1995;87:1077-81.
16. Kearns CM, Giani L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22(Suppl 6):16-23.
17. Kearns, CM, Gianni L, Vigano L, et al. Validation of paclitaxel limited sampling strategies. Proc Am Soc Clin Oncol 1997;16:206a.
18. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
19. Chen Y, Pandya K, Keng P, et al. Pharmacokinetics of low-dose paclitaxel: toxicity of phase I study and implication for radiosensitization for non-small cell lung cancer in vivo. Proc Am Soc Clin Oncol 2002;21:120a.
20. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995;1:599-606.
21. Beijnen JH, Huizing MT, ten Bokkel Huinink WW, et al. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Semin Oncol 1994;21(Suppl 8):53-62.
22. Smorenburg CH, Sparreboom A, Bontenbal M, et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003;21:197-202.
23. Rahman A, Korzekwa KR, Grohan J, et al. Selective biotransformation of taxol to 6 alpha-hydrotaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-6.
24. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94:2031-5.
25. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607.
26. Tayeb MT, Clark C, Ameyaw MM, et al. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000;10:753-6.
27. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001;11:217-21.